Calithera Biosciences - CALA Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CALA shares.
View CALA analyst ratings or view top-rated stocks.

4 brokerages have issued 12 month price objectives for Calithera Biosciences' stock. Their CALA share price forecasts range from $30.00 to $40.00. On average, they expect the company's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 777.2% from the stock's current price.
View analysts price targets for CALA or view top-rated stocks among Wall Street analysts.

Calithera Biosciences' stock was trading at $13.30 at the beginning of 2022. Since then, CALA stock has decreased by 70.0% and is now trading at $3.99.
View the best growth stocks for 2022 here.

Calithera Biosciences saw a drop in short interest in July. As of July 15th, there was short interest totaling 144,200 shares, a drop of 27.2% from the June 30th total of 198,100 shares. Based on an average trading volume of 174,900 shares, the days-to-cover ratio is currently 0.8 days. Currently, 3.2% of the shares of the stock are sold short.
View Calithera Biosciences' Short Interest.

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our CALA earnings forecast.

Calithera Biosciences, Inc. (NASDAQ:CALA) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, beating analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter. During the same period last year, the firm earned ($6.40) EPS.

Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Calithera Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include TSP Capital Management Group LLC (1.10%) and Tarbox Family Office Inc. (0.21%). Insiders that own company stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong, Susan Molineaux and Value Fund L P Biotechnology.
View institutional ownership trends.

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CALA stock can currently be purchased for approximately $3.99.

Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $19.40 million and generates $9.75 million in revenue each year. The biotechnology company earns $-115,090,000.00 in net income (profit) each year or ($28.80) on an earnings per share basis.

Calithera Biosciences employs 92 workers across the globe.

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com.